Artelo Biosciences Inc. has entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC - Series 5, allowing the company to direct Square Gate to purchase up to $25 million in shares of common stock, with the option to increase this by an additional $25 million once the initial amount is exhausted. The sale of shares under this agreement is being conducted as a private placement and is unregistered, relying on exemptions from registration under federal and state securities laws. The agreement is set to remain in effect until the total commitment amount is reached or until January 30, 2029, unless terminated earlier under specified conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-000227), on February 05, 2026, and is solely responsible for the information contained therein.